Prophylaxis for Aspiration of Gastric Contents.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

1920 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Effect of orally administered two equal and consecutive doses of proton pump inhibitors, omeprazole, lansoprazole, esomeprazole , rabeprazole and pantoprazole and Histamine 2 receptor antagonists cimetidine, ranitidine,famotidine,nizatidine and lafutidine without and with a prokinetic agents domperidone, metoclopramide and erythromycin on intragastric pH, volume and bile refluxate.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Low Dose of Proton Pump Inhibitor in Treatment Bleeding Ulcers

NCT03163680

Gastroduodenal Ulcer Marginal Ulcer Peptic Ulcer Hemorrhage

COMPLETED

Study of Proton Pump Inhibitors (PPI) to Prevent Strictures After Gastric Bypass Surgery

NCT00361985

Anastomotic Stricture Morbid Obesity

WITHDRAWN PHASE4

Comparison of Low Against High Regimen of Proton Pump Inhibitors for Treatment of Acute Peptic Ulcer Bleeding

NCT02724150

Gastroduodenal Ulcer Marginal Ulcer Peptic Ulcer Hemorrhage

WITHDRAWN PHASE4

Trial of Oral Versus Intravenous Proton Pump Inhibitor on Intragastric pH in Patients With Bleeding Ulcers

NCT00573924

Peptic Ulcer Hemorrhage

COMPLETED NA

Re-Evaluating the Inhibition of Stress Erosions: Gastrointestinal Bleeding Prophylaxis In ICU

NCT02290327

Stress Ulcer Prophylaxis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

(This description is for one drug and similar for other drugs) We repacked the placebo, lansoprazole 15 mg and lansoprazole 15 mg plus domperidone 10 mg in 180 envelopes (times two) and then two envelope in one envelope each for evening and morning of the same size, shape and color and their name were changed as drug one, drug two and drug three by a person who was not taking part in the study to the patients (single-blind) and investigators (double-blind) blinded of it. The group assign paper was sealed in another envelope that was opened to know which drug corresponds to either drug one or drug two or drug three after the statistical analysis(triple-blind).

On the preoperative anaesthesia visit, a day before surgery, the nature and purpose of the study was explained to each patient. We asked each patient to pick up on one envelop from the envelopes (randomization). Thus the patients were allocated to either Group C (control), Group L lansoprazole 15 mg or Group LD lansoprazole 15 mg with domperidone 10 mg randomly by sealed envelope method. Age, sex, ASA physical status, weight, height, BMI and the study drug given were recorded for each patient. All patients also received tablet diazepam 5 mg with study drugs. These drugs were given orally with 20 ml of drinking water at 8:00 p.m. in the evening day before surgery and 6:00 a.m. morning on the day of surgery. According to the hospital policy, all patients were fasted from 12:00 midnight. Upon arrival in the receiving area of the operating room. All patients were asked if they had been aware of any unusual feeling (side effect) after taking the study drug.

In the operating room, routine monitors were attached to the patients and turned on. After pre-oxygenation with 100% O2 by face mask using eight breaths vital capacity method, anaesthesia was induced with injection fentanyl 1-2 mcg/kg, propofol 2-3 mg/kg and rocuronium 0.6-0.9 mg/kg. Lungs were ventilated taking care not to inflate the stomach. Maintaining cricoid pressure trachea was intubated with cuffed endotracheal tube. Placement and position was confirmed with EtCO2 monitor and then secured properly. After establishing stable anaesthesia, an endotracheal tube sized 8.5 internal diameter was passed via oral route in the esophagus with anterior displacement of larynx. A predetermined length marked with adhesive tape (xiphoid process to ear lobule- fro ear lobule to nasal tip) of stomach tube sized 18 F was passed through the esophageally placed endotracheal tube. Placement of this tube within the stomach was verified with auscultation over the epigastrium during insufflation of 10-15 ml of air. Gastric contents were gently aspirated manually with 60 ml syringe by an investigator who was blind of group assignment. Applying manual pressure over the epigastrium while the patient was in supine and then left and right lateral positions, gastric tube was then manipulated to ensure maximum emptying of gastric contents. The stomach tube was then removed followed by esophageally placed endotracheal tube. Any problem encountered during inserting or removing the oro-esophageally placed endotracheal tube or gastric tube was also recorded. The volume of gastric contents was measured with graduated syringe and pH using pH meter. The pH meter was calibrated using standard buffers at pH values of 4, 7 and 9.20. This pH meter has a precision of 0.01 units over the entire pH range. A minimum of one-millimeter volume of gastric contents was sufficient for pH determination with pH meter. In case of very little amount of gastric contents, we cut the stomach tube and aspirated gastric material with disposable plastic pipette. Samples less than one-millimeter were considered as no gastric contents because a minimum of one- millimeter of gastric contents was sufficient for pH- metry. Using bile salts as marker for bile, we applied qualitative Hay's sulphur test for the presence of bile salts. A minimum volume of one millimeter of gastric contents was adequate to perform Hay's sulphur test. In this test finely powered sulphur is sprinkled on the surface of cool (17 OC or below) liquid. If bile salts are present sulphur sinks down, sooner or later, in accordance with their percentage. If bile salts are present in from 1:5,000 (0.02%or 200 mcg/ml to 1:10,000 (0.01% or 100 mcg/ml) sulphur at once begins to sink and all precipitated in two or three minutes; even in dilution of 1:120,000 (0.0008% or 8.33 mcg/ml precipitation occurs. On the other hand, if sulphur remains floating on the surface, bile salts are absent.

Anaesthesia was maintained with air, O2 and sevoflorane. Patients also received incremental doses of fentanyl and rocuronium as required. At the end of surgery, injection atropine and neostigmine were given to antagonize the residual effect of rocuronium. All patients were extubated in lateral position and then transferred to recovery room.

Time since premedication T1 (time from evening dose till aspiration of gastric contents) and Time since premedicationT2 (time from morning dose till aspiration of gastric contents), pH, volume of gastric contents and results of Hay's sulphur test were also recorded for all patients.

Statistical test were performed using GraphPad Software, Inc., San Diego, United States and results are expressed as absolute values or mean ± standard deviation SD (SEM). Statistical analysis between the groups were carried out using analysis of variance (ANOVA) for age, BMI, time since premedication T1, time since NPO and T2 , pH and volume. Chi square test was applied for sex, ASA physical status, Hay's test and risk of aspiration according to criteria defined (pH ≤ 2.5 and volume ≥ 0.4ml/kg or 25 ml. Post hoc tests with Bonferrni correction applied where p-value significant(p \<0,05). A p-value of less than 0.05 was considered statistically significant. Power analysis revealed that the sample size (n= 30) in each group was of the study was sufficient to detect a difference of 0.7 among the groups in gastric pH and volume at a significant level of 0.05 (=α 0 with a power of 0.85.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Aspiration of Gastric Contents

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Intervention Type PROCEDURE

OGT insertion:Insertion of orogastric tube(through an endotracheal tube placed in the upper esophagus) into the stomach after general anaesthesia.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Drug either PPIS or H2RA and prokinetics

Drug intervention ( dose unit mg) Two oral doses 8:00 p.m. and 6:00 a.m. (n=60) total 10 groups

1. Group C (placebo),Group L (lansoprazole15 ), Group LD (Lansoprazole 15 +domperidone 10 )
2. Group C ,R (rabeprazole 10), RM (rabeprazole 10 + metoclopramide 10)
3. Group C , E (esomeprazole 20 ), and EM (esomeprazole 20 + metoclopramide 10)
4. Group C, P (pantoprazole 20), and PD (pantoprazole 20 + domperidone 10 mg)
5. Group C, O (omeprazole 20), OD (omeprazole 20 + domepridone 10), OM (omeprazole 20 + metoclopramide 10)
6. Group C,T (cimetidine 200), TD (cimetidine 200 + domperidone 10)
7. Group C , Z (ranitidine 150), ZD (ranitidine 150 + domperidone 10)
8. Group C , N (nizatidine 150),NM (nizatidine 150 + metoclopramide 10)
9. Group C, F (famotidine 20 mg), and FM (famotidine 20 mg + metoclopramide 10)
10. Group C,S (lafutidine 10), SD (lafutidine 10 + domperidone 10), and Group SM (lafutidine 10 + metoclopramide 10)

Intervention Type DRUG

orogastric intubation

OGT insertion:Insertion of orogastric tube(through an endotracheal tube placed in the upper esophagus) into the stomach after general anaesthesia.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Drug treatment lansoprazole, esomeprazole,pantoprazole,rebeprazole, omeprazole,cimetidine,nizatidine,famotidine,ranitidine,lafutidine OGT Insertion

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\-

Exclusion Criteria

Patients with upper gastrointestinal disorders, Body mass index above 35 kg/m2, Receiving medicines known to effect the secretory and or motor functions of stomach, Had undergone surgery on stomach, With difficult intubation Intestinal obstruction, Partuients and Diabetes

.

\-

Minimum Eligible Age

15 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes